drugset / Trial / NCT06946199
An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis
Phase 1
Recruiting
28 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.
Timeline
- Start
- 2025-06-23
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cizutamig | Protein / enzyme biologic | — | — |